Navigation Links
Barriers to obtaining gene expression profiling test heightened perceived value
Date:6/17/2014

Barriers to obtaining gene expression profiling test heightened perceived value among patients, new study says TORONTO, June 17, 2014Barriers to obtaining gene expression profiling tests heightened their perceived importance among patients with early breast cancer who were deciding whether to have chemotherapy, a new study says.

Gene expression profiling tests, such as Oncotype Dx, analyze the patterns of 21 different genes within cancer cells to help predict how likely it is that a women's cancer will recur within 10 years after initial treatment and how beneficial chemotherapy will be to her.

Dr. Yvonne Bombard, a genomics and health services researcher in the Li Ka Shing Knowledge Institute of St. Michael's Hospital, found that access to this newly available and expensive technology is subject to careful administration and oversight.

However, she said that has created unintended consequences such as making oncologists gatekeepers for determining when it was medically appropriate for someone to have the test, leading to perceived inequalities in access by patients. Moreover, media attention made patients more aware of the gene expression profiling tests and led them to specifically ask for them, but that complicated physicians' gatekeeping efforts, sometimes hurting the doctor-patient relationship.

"There was a sense that the test was scarce or difficult to obtain, which heightened patients' desire for it and led them to perceive gene expression profiling tests as the deciding factor in their chemotherapy decisions, over and above other clinical tests and indicators," she said.

Dr. Bombard interviewed 14 oncologists and 28 breast cancer patients in Ontario for a study published today in Current Oncology. Ontario was the first province in Canada to fund gene expression profiling tests.

She said the careful oversight required of oncologists to the test created perceived inequities in access among patients. This often occurred in how oncologists discussed the test with their patients. Some oncologists offered the test to all their patients; others only to those who were eligible or where they felt there was uncertainty about the potential value of chemotherapy. Some raised it early in their consultations with patients, others late in the process, leading some patients to feel their doctors had already made the decision to recommend chemotherapy. Dr. Bombard said some patients felt information about the test was not offered to them because of its high cost, $4,000.

"Such delays or omissions in mentioning the test often left patients confused or feeling that something of great value was being withheld," she said.

Some patients said they learned about the tests from media reports describing a lack of funding in Canada that framed the issue as one of inequitable access to a highly effective, game-changing technology. Several of the oncologists said they felt pressured by the media coverage to offer the test to women for whom they knew it would not provide useful information for their decision-making about chemotherapy.

Another barrier was the extra paperwork around the test, which is not performed in Canada. Patients and oncologists must fill out forms to establish eligibility for OHIP reimbursement. Oncologists were then required to obtain government approval before sending tumour samples out of the country for testing. Results usually take about three weeks. This extra paperwork was cumbersome, increased anxieties about missing the window to start treatment and also reinforced the impression that the test was special, because it warranted special attention.


'/>"/>

Contact: Leslie Shepherd
shepherdl@smh.ca
416-864-6094
St. Michael's Hospital
Source:Eurekalert  

Related medicine news :

1. Study identifies barriers to breast health care in Pakistan
2. Kicking the habit -- new research examines the barriers to quitting smoking for smokers with asthma
3. Cultural, social factors identified as barriers to minority participation in stem cell donation
4. Personalized plans to address barriers to HIV drug adherence boost chances of successful therapy
5. Baylor University researchers study barriers, resources to physical activity in Texas towns
6. Affordable care alone may not be enough to help Latinos overcome cancer care barriers
7. Kids on Medicaid May Face Barriers to Eczema Treatment
8. Experts to present data addressing patient and physician barriers to clinical trials
9. BroadConnect Is Offering New Hosted PBX Bundle Pricing for New Customers, Eliminating VoIP Adoption Barriers
10. Research examines how technology can break down barriers
11. Egg-allergic children now have no barriers to flu shot
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Barriers to obtaining gene expression profiling test heightened perceived value
(Date:3/29/2017)... Ca (PRWEB) , ... March 29, 2017 , ... ... process in many scientific laboratories. The assembly protocols involve many repetitive steps and ... suited for automation, which enables the high-throughput needed, and results in a lower ...
(Date:3/29/2017)... ... March 29, 2017 , ... Hamlin Dental Group, multi-location ... now offering laser dental treatments. Dental lasers are safe and effective options, and can ... options and can improve the overall quality of care. , Dr. Hamid Reza of ...
(Date:3/29/2017)... ... March 29, 2017 , ... Physicians’ Education Resource® (PER®), ... medical education conference for clinicians who manage some of the most difficult-to-treat forms ... , The program will be led by co- chairs Dr. John Marshall, chief ...
(Date:3/29/2017)... ... March 29, 2017 , ... AvePoint , the Microsoft Cloud expert, is ... Richmond, Virginia, located at the Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating ... Ralph S. Northam and Mayor of Richmond Levar M. Stoney. , Founded in 2001, ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... in order to improve teacher quality, the field must first improve teacher preparation ... popular reform to the next” and that decades of input- and outcome-based research ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... March 28, 2017  Medeon Biodesign, Inc., a ... is pleased to announce that the Company led ... Panther Orthopedics, Inc., a San Jose, ... solutions for orthopedic extremity applications.  ... rapidly, primarily due to procedure volume growth, lifestyle ...
(Date:3/28/2017)...  "US Cancer Generics Market Outlook 2022" report ... trend analysis related to the emergence and integration ... in US. The report analyzes various clinical and ... generics drugs in recent years. The introduction of ... dollars for various stake holders involved US cancer ...
(Date:3/28/2017)... 2017  Orexigen Therapeutics, Inc. (Nasdaq: OREX ... fourth quarter and year ended December 31, 2016. ... progress for Orexigen, beginning with the re-acquisition of the ... March, the team at Orexigen demonstrated remarkable focus, executing ... and strengthened our Company while rewarding us full control ...
Breaking Medicine Technology: